This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.90% per year. These returns cover a period from January 1, 1988 through December 1, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
earnings-estimates-revisions: Archive
ELUTIA INC (ELUT) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ELUTIA INC (ELUT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ELUTPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Cactus (WHD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Cactus (WHD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
WHDNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Prenetics Global (PRE) Rating Upgrade to Buy
by Zacks Equity Research
Prenetics Global (PRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
PREPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
USCB Financial (USCB) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
USCB Financial (USCB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
USCBNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
All You Need to Know About Encompass Health (EHC) Rating Upgrade to Buy
by Zacks Equity Research
Encompass Health (EHC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
EHCNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Acuity (AYI) Upgraded to Buy: Here's Why
by Zacks Equity Research
Acuity (AYI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AYINegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Gitlab (GTLB) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Gitlab (GTLB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
GTLBNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Contineum Therapeutics, Inc. (CTNM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
CTNMPositive Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
What Makes Steven Madden (SHOO) a New Strong Buy Stock
by Zacks Equity Research
Steven Madden (SHOO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SHOONegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Baytex (BTE) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Baytex (BTE) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BTENegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Earnings Preview: Kura Sushi (KRUS) Q1 Earnings Expected to Decline
by Zacks Equity Research
Kura Sushi (KRUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
KRUSPositive Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Analysts Estimate Jefferies (JEF) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Jefferies (JEF) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
JEFNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Earnings Preview: Constellation Brands (STZ) Q3 Earnings Expected to Decline
by Zacks Equity Research
Constellation Brands (STZ) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STZNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Franklin Covey (FC) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Franklin Covey (FC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
FCNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
AZZ (AZZ) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
AZZ (AZZ) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
AZZNegative Net Change
consensus-outlook earnings earnings-consensus earnings-esp earnings-estimates-revisions earnings-expectations earnings-preview stock-price-change zacks-consensus-estimate
Wall Street Analysts See a 68.54% Upside in WeRide Inc. (WRD): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 68.5% upside potential for WeRide Inc. (WRD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
WRDNegative Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 60.47% Upside in Ooma (OOMA): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Ooma (OOMA) points to a 60.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
OOMAPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Analysts See a 91.49% Upside in Contineum Therapeutics, Inc. (CTNM): Can the Stock Really Move This High?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 91.5% in Contineum Therapeutics, Inc. (CTNM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
CTNMPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Does Daktronics (DAKT) Have the Potential to Rally 29.17% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 29.2% in Daktronics (DAKT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
DAKTPositive Net Change
earnings-consensus earnings-estimates-revisions zacks-consensus-estimate
Wall Street Bulls Look Optimistic About Superior Group (SGC): Should You Buy?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Superior Group (SGC) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
SGCNegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Analysts Think Ouster (OUST) Is a Good Investment: Is It?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Ouster (OUST). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
OUSTPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Wall Street Bulls Look Optimistic About TXO Partners LP (TXO): Should You Buy?
by Zacks Equity Research
The average brokerage recommendation (ABR) for TXO Partners LP (TXO) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
TXOPositive Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is It Worth Investing in Itron (ITRI) Based on Wall Street's Bullish Views?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), Itron (ITRI) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
ITRINegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
Is Consolidated Water (CWCO) a Buy as Wall Street Analysts Look Optimistic?
by Zacks Equity Research
According to the average brokerage recommendation (ABR), one should invest in Consolidated Water (CWCO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
CWCONegative Net Change
broker-rating earnings-estimates-revisions earnings-growth
AudioEye (AEYE) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
The average brokerage recommendation (ABR) for AudioEye (AEYE) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
AEYENegative Net Change
broker-rating earnings-estimates-revisions earnings-growth